# INCB161734

Source: https://onco.cc/drugs/incb161734/  
OnCo record `incb161734` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INCB161734 is an experimental small-molecule drug from Incyte in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at KRAS.

## Summary

INCB161734 is a small-molecule drug developed by Incyte. Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: An oral tablet identified on the trial page as a KRAS G12D inhibitor, evaluated in combination with standard chemotherapy (mFOLFIRINOX or GemNabP) versus chemotherapy alone in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07522073, plans to enrol 588 participants with primary completion expected 2028-09-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: An oral tablet identified on the trial page as a KRAS G12D inhibitor, evaluated in combination with standard chemotherapy (mFOLFIRINOX or GemNabP) versus chemotherapy alone in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma.

## Sources

- ClinicalTrials.gov: trials of INCB161734: https://clinicaltrials.gov/search?intr=INCB161734

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Incyte](https://onco.cc/companies/incyte/)
- trials: [A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct07522073/)

---
JSON: https://onco.cc/api/v1/entities/incb161734.json